Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry.
about
Directly coupled high-performance liquid chromatography-accelerator mass spectrometry measurement of chemically modified protein and peptidesAssessment of Protein Binding of 5-Hydroxythalidomide Bioactivated in Humanized Mice with Human P450 3A-Chromosome or Hepatocytes by Two-Dimensional Electrophoresis/Accelerator Mass Spectrometry.Combining Chimeric Mice with Humanized Liver, Mass Spectrometry, and Physiologically-Based Pharmacokinetic Modeling in Toxicology.Chimeric mice transplanted with human hepatocytes as a model for prediction of human drug metabolism and pharmacokinetics.Current status of prediction of drug disposition and toxicity in humans using chimeric mice with humanized liver.Troglitazone metabolism and transporter effects in chimeric mice: a comparison between chimeric humanized and chimeric murinized FRG mice.Different metabolites of human hepatotoxic pyrazolopyrimidine derivative 5-n-butyl-pyrazolo[1,5-a]pyrimidine produced by human, rat and monkey cytochrome P450 1A2 and liver microsomes.Evaluation of the Utility of Chimeric Mice with Humanized Livers for the Characterization and Profiling of the Metabolites of a Selective Inhibitor (YM543) of the Sodium-Glucose Cotransporter 2.Pharmacokinetics and metabolism of midazolam in chimeric mice with humanised livers.Identification and characterization of metabolites of ASP015K, a novel oral Janus kinase inhibitor, in rats, chimeric mice with humanized liver, and humans.Zone analysis by two-dimensional electrophoresis with accelerator mass spectrometry of in vivo protein bindings of idiosyncratic hepatotoxicants troglitazone and flutamide bioactivated in chimeric mice with humanized liver
P2860
Q33664945-3B26C582-D7EA-4195-801B-AFB2B4477B72Q37616087-BD887FD8-BACE-48AE-99DF-2FDE570E1335Q37624853-255CD2D0-075F-4359-8A80-022E1AA11EEBQ38151571-9B7B4FC7-7CE2-43CC-AB62-DCA60FED8AA5Q38170468-E2A283A2-A938-46C7-AC85-94382F4177BCQ44279130-B542D1E3-5B12-440F-8DAB-3B8C9FACA677Q45045116-209FF4AB-3914-4C06-8924-6D6BA177541FQ46418279-2741D960-0D30-4624-A4C0-3AD995F84096Q47698358-7A079DE1-E3D8-41C2-903B-EFE1EBD1A8E3Q54278269-BF461759-C161-47F7-B742-1AF10D0F69C7Q59153006-4591E5DD-D2C8-4D41-B381-8A33A1F8F106
P2860
Approach for in vivo protein binding of 5-n-butyl-pyrazolo[1,5-a]pyrimidine bioactivated in chimeric mice with humanized liver by two-dimensional electrophoresis with accelerator mass spectrometry.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Approach for in vivo protein b ...... accelerator mass spectrometry.
@en
Approach for in vivo protein b ...... accelerator mass spectrometry.
@nl
type
label
Approach for in vivo protein b ...... accelerator mass spectrometry.
@en
Approach for in vivo protein b ...... accelerator mass spectrometry.
@nl
prefLabel
Approach for in vivo protein b ...... accelerator mass spectrometry.
@en
Approach for in vivo protein b ...... accelerator mass spectrometry.
@nl
P2093
P356
P1476
Approach for in vivo protein b ...... accelerator mass spectrometry.
@en
P2093
Chise Tateno
Daisuke Harada
Ken Oofusa
Shigeru Ohta
Shinsaku Naito
Shunji Kuribayashi
Toru Horie
Yasufumi Nishikura
P304
P356
10.1021/TX900323A
P577
2010-01-01T00:00:00Z